Dr. Martens (LON:DOCS) Shares Down 13.7% – Time to Sell?

Dr. Martens plc (LON:DOCS) shares fell 13.7% during mid-day trading on Tuesday . The stock traded as low as GBX 65 and last traded at GBX 65.29. 3,337,086 shares changed hands during trading, an increase of 93% from the average session volume of 1,727,242 shares. The stock had previously closed at GBX 75.65.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on DOCS. Berenberg Bank reissued a “buy” rating on shares of Dr. Martens in a research note on Thursday, November 27th. Peel Hunt restated a “buy” rating on shares of Dr. Martens in a research note on Thursday, November 20th. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 6,000.

Dr. Martens Price Performance

The company has a current ratio of 2.85, a quick ratio of 1.13 and a debt-to-equity ratio of 127.27. The stock has a market cap of £634.55 million, a PE ratio of 38.62, a P/E/G ratio of 6.40 and a beta of 0.11. The company’s 50 day moving average is GBX 76.53 and its 200-day moving average is GBX 83.47.

Dr. Martens (LON:DOCS) last announced its earnings results on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. As a group, sell-side analysts predict that Dr. Martens plc will post 2.5809394 earnings per share for the current year.

Insiders Place Their Bets

In other Dr. Martens news, insider Robert Hanson acquired 96,000 shares of the company’s stock in a transaction on Friday, December 5th. The shares were bought at an average cost of GBX 79 per share, for a total transaction of £75,840. In the last ninety days, insiders purchased 97,130 shares of company stock worth $7,673,816. 2.79% of the stock is owned by company insiders.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.